Bioventus Inc. raised earnings guidance for the twelve months ending December 31, 2023. For the period, the company now expects net sales to be between $498 million to $505 million, an increase in the midpoint from company's previous guidance of $490 million to $505 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.72 USD | +5.93% | +43.00% | +8.54% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.54% | 345M | |
+73.37% | 12.41B | |
-18.59% | 8.23B | |
-0.90% | 6.46B | |
+15.76% | 5.5B | |
-4.95% | 5.33B | |
+40.80% | 5.1B | |
-17.52% | 4.05B | |
-29.79% | 2.54B | |
+7.56% | 1.99B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Raises Earnings Guidance for the Twelve Months Ending December 31, 2023